Ryosuke Imai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ryosuke Imai has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Torahiko Jinta
Department of Pulmonary Medicine, Thoracic Center, and
9 shared publicationsNaoki Nishimura
Department of Pulmonary Medicine, Thoracic Center, and
7 shared publicationsYutaka Tomishima
Department of Pulmonary Medicine, Thoracic Center, and
5 shared publications- Andrew J. Synn
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, Harvard Medical School, Boston, MA, USA
4 shared publications - Mary Berlik Rice
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, Harvard Medical School, Boston, MA, USA
4 shared publications - Naoki Nishimura
Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
4 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (3)
Beyond IPF: Pulmonary Function Test Predictors of Echocardiographic Pulmonary Hypertension Across the Spectrum of ILD
Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD), yet data on screening in heterogenous ILD populations are limited. We evaluated whether routinely measured pulmonary function test (PFT) parameters identify individuals with intermediate‐to‐high echocardiographic risk of PH. 432 ILD patients met inclusion criteria with an echocardiogram reporting peak tricuspid regurgitant velocity (TRV) and a PFT reporting diffusion impairment (DLCO) within 1 year (median interval, 39 days). Of these, 126 underwent right heart catheterization (RHC). Age‐ and sex‐ adjusted logistic regression assessed associations between %predicted forced vital capacity (FVC), %predicted DLCO, and FVC/DLCO ratio with intermediate‐to‐high echocardiographic PH probability (TRV > 2.8 m/s). Receiver operating characteristic curves evaluated diagnostic performance. The cohort included 28% systemic autoimmune rheumatic disease‐associated ILD, 27% interstitial pneumonia with autoimmune features, and 6% idiopathic pulmonary fibrosis, with a mean age of 72% and 54% female. Lower FVC and DLCO were associated with higher odds of echocardiographic PH (OR 1.35, 95%CI 1.21–1.50; OR 1.50, 95%CI 1.36–1.73) and increases in FVC/DLCO ratio similarly predicted risk (OR 1.83, 95%CI 1.44–2.32). DLCO had the highest predictive ability (AUC 0.74, 95%CI 0.69–0.79) with an optimal cut‐off of 42% (sensitivity 67%, specificity 74%). In patients who underwent RHC, TRV > 2.8 m/s correlated with mean pulmonary artery pressure (r = 0.55, 95%CI 0.42–0.66) and tripled the odds of confirmed PH (OR 3.75, 95%CI 2.25–6.24). In sum, severe diffusion impairment, regardless of fibrosis extent, may detect patients with ILD who warrant echocardiographic screening, specialty PH referral, and consideration of RHC.
- 1 July 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (3)
Open AccessBeyond IPF: Pulmonary Function Test Predictors of Echocardiographic Pulmonary Hypertension Across the Spectrum of ILD
Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD), yet data on screening in heterogenous ILD populations are limited. We evaluated whether routinely measured pulmonary function test (PFT) parameters identify individuals with intermediate‐to‐high echocardiographic risk of PH. 432 ILD patients met inclusion criteria with an echocardiogram reporting peak tricuspid regurgitant velocity (TRV) and a PFT reporting diffusion impairment (DLCO) within 1 year (median interval, 39 days). Of these, 126 underwent right heart catheterization (RHC). Age‐ and sex‐ adjusted logistic regression assessed associations between %predicted forced vital capacity (FVC), %predicted DLCO, and FVC/DLCO ratio with intermediate‐to‐high echocardiographic PH probability (TRV > 2.8 m/s). Receiver operating characteristic curves evaluated diagnostic performance. The cohort included 28% systemic autoimmune rheumatic disease‐associated ILD, 27% interstitial pneumonia with autoimmune features, and 6% idiopathic pulmonary fibrosis, with a mean age of 72% and 54% female. Lower FVC and DLCO were associated with higher odds of echocardiographic PH (OR 1.35, 95%CI 1.21–1.50; OR 1.50, 95%CI 1.36–1.73) and increases in FVC/DLCO ratio similarly predicted risk (OR 1.83, 95%CI 1.44–2.32). DLCO had the highest predictive ability (AUC 0.74, 95%CI 0.69–0.79) with an optimal cut‐off of 42% (sensitivity 67%, specificity 74%). In patients who underwent RHC, TRV > 2.8 m/s correlated with mean pulmonary artery pressure (r = 0.55, 95%CI 0.42–0.66) and tripled the odds of confirmed PH (OR 3.75, 95%CI 2.25–6.24). In sum, severe diffusion impairment, regardless of fibrosis extent, may detect patients with ILD who warrant echocardiographic screening, specialty PH referral, and consideration of RHC.
- Open Access
- 21 February 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (5) , 911-920
Comparison of oxygenation targets in critically ill adults: a systematic review and network meta-analysis of randomized controlled trials
Ryosuke Imai, MD, MMSc, Ryohei Yamamoto, MD, PhD, Takayuki Niitsu, MD, Ann-Marcia C Tukpah, MD, MPH, MS, Ryo Kamidani, MD, PhD, Hiroki Sato, PhD, Yohei Iwa
- 21 February 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (5) , 911-920
Open AccessComparison of oxygenation targets in critically ill adults: a systematic review and network meta-analysis of randomized controlled trials
Ryosuke Imai, MD, MMSc, Ryohei Yamamoto, MD, PhD, Takayuki Niitsu, MD, Ann-Marcia C Tukpah, MD, MPH, MS, Ryo Kamidani, MD, PhD, Hiroki Sato, PhD, Yohei Iwa
- 25 January 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 724-733
Longitudinal Changes in Serum Urate Levels From Premenopause Through Postmenopause: Interrupted Time‐Series Analyses
Objective: Hyperuricemia (HU) and gout are common in postmenopausal women. We aimed to identify the longitudinal changes in serum urate (SU) levels during and after the menopausal transition and its interaction with coexisting SU‐modifying conditions. Methods: This longitudinal study included Japanese women who underwent annual medical examinations from April 2004 to September 2024 and had at least one visit before and after self‐reported menopause. Menopausal transition stages were categorized into premenopause, perimenopause (5 years before and up to the menopause), and postmenopause. Longitudinal changes in SU and HU (SU ≥6.8 mg/dL or taking medications for gout or HU) were examined by interrupted time‐series analyses and evaluated across stratified subgroups. Results: We analyzed 8,169 eligible participants with 93,511 visits over a median follow‐up of 13.8 years. SU levels gradually increased during premenopause, rose sharply over perimenopause, and stabilized in postmenopause. Compared to premenopause, the mean SU level was 0.41 mg/dL (95% confidence interval: 0.38–0.43) higher in postmenopause. HU prevalence increased from 2 ) and a high body mass index (≥25) with HU were greater in postmenopause; HU was observed in approximately 18% of overweight or obese women at menopause. Conclusion: SU levels rapidly increase during perimenopause and are already elevated by the time of menopause. Maintaining a normal body weight and preserving kidney function before menopause may decrease postmenopausal HU and potentially prevent subsequent gout in women. image
- 25 January 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 724-733
Longitudinal Changes in Serum Urate Levels From Premenopause Through Postmenopause: Interrupted Time‐Series Analyses
Objective: Hyperuricemia (HU) and gout are common in postmenopausal women. We aimed to identify the longitudinal changes in serum urate (SU) levels during and after the menopausal transition and its interaction with coexisting SU‐modifying conditions. Methods: This longitudinal study included Japanese women who underwent annual medical examinations from April 2004 to September 2024 and had at least one visit before and after self‐reported menopause. Menopausal transition stages were categorized into premenopause, perimenopause (5 years before and up to the menopause), and postmenopause. Longitudinal changes in SU and HU (SU ≥6.8 mg/dL or taking medications for gout or HU) were examined by interrupted time‐series analyses and evaluated across stratified subgroups. Results: We analyzed 8,169 eligible participants with 93,511 visits over a median follow‐up of 13.8 years. SU levels gradually increased during premenopause, rose sharply over perimenopause, and stabilized in postmenopause. Compared to premenopause, the mean SU level was 0.41 mg/dL (95% confidence interval: 0.38–0.43) higher in postmenopause. HU prevalence increased from 2 ) and a high body mass index (≥25) with HU were greater in postmenopause; HU was observed in approximately 18% of overweight or obese women at menopause. Conclusion: SU levels rapidly increase during perimenopause and are already elevated by the time of menopause. Maintaining a normal body weight and preserving kidney function before menopause may decrease postmenopausal HU and potentially prevent subsequent gout in women. image
- Open Access
- 5 December 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (1) , 2501638
Low forced vital capacity is associated with poor prognosis in physiologically stable non-IPF interstitial lung disease
Current guidelines define progressive pulmonary fibrosis (PPF) as the presence of at least two of the following three changes within 12 months: worsening symptoms, lung function decline, or new/extending radiographic abnormalities [1, 2]. However, limiting assessment to subsequent progression may miss high-risk patients: those presenting with severely impaired lung function may meet none of the criteria if later tests remain unchanged, delaying therapy initiation and close monitoring. Therefore, we examined whether baseline forced vital capacity (FVC) was associated with an increased risk of lung transplantation or death in non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung disease (ILD) patients whose FVC declined by <5 percentage points predicted during the first year after diagnosis.
- 5 December 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (1) , 2501638
Open AccessLow forced vital capacity is associated with poor prognosis in physiologically stable non-IPF interstitial lung disease
Current guidelines define progressive pulmonary fibrosis (PPF) as the presence of at least two of the following three changes within 12 months: worsening symptoms, lung function decline, or new/extending radiographic abnormalities [1, 2]. However, limiting assessment to subsequent progression may miss high-risk patients: those presenting with severely impaired lung function may meet none of the criteria if later tests remain unchanged, delaying therapy initiation and close monitoring. Therefore, we examined whether baseline forced vital capacity (FVC) was associated with an increased risk of lung transplantation or death in non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung disease (ILD) patients whose FVC declined by <5 percentage points predicted during the first year after diagnosis.
- 17 September 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (3) , 2500453
Pirfenidone and lung cancer in idiopathic pulmonary fibrosis: mind the index date, detection bias and competing risks
- 17 September 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (3) , 2500453
Pirfenidone and lung cancer in idiopathic pulmonary fibrosis: mind the index date, detection bias and competing risks
- Open Access
- 2 September 2025
- Published by Elsevier in CHEST Critical Care
- Vol. 3 (4)
Comparison of Corticosteroid Regimens for COVID-19 and Non-COVID-19 ARDS
- 2 September 2025
- Published by Elsevier in CHEST Critical Care
- Vol. 3 (4)
Open AccessComparison of Corticosteroid Regimens for COVID-19 and Non-COVID-19 ARDS
- 1 March 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (3) , 387-394
Prognosis of Equivocal Interstitial Lung Abnormalities in a Health Check-Up Population
Rationale: Equivocal interstitial lung abnormality (ILA) involves less than 5% of any lung zone or presents unilaterally without satisfying the diagnostic criteria for ILA. However, the prevalence and prognosis of equivocal ILA are unknown. Objectives: We sought to investigate the prevalence and long-term prognosis of equivocal ILA. Methods: This retrospective cohort study included individuals who underwent chest computed tomography as part of a health check-up program in 2010 at St. Luke’s International Hospital in Tokyo, Japan. ILA and equivocal ILA were diagnosed using the Fleischner Society criteria. The primary outcome was the annual rate of forced vital capacity (FVC) decline in the groups with ILA, equivocal ILA, and no ILA, evaluated using a mixed-effects model. Radiological progression was also evaluated. Results: Among the 20,896 individuals included in the study, ILA and equivocal ILA were present in 2.0% (95% confidence interval = 1.8–2.2) and 0.4% (95% confidence interval = 0.4–0.5) of individuals, respectively. Follow-up pulmonary function tests were available for 18,101 (87%) individuals, with a median follow-up time of 8.3 years (interquartile range = 4.0–9.0). Individuals with equivocal ILA showed a significantly greater rate of FVC decline than those without ILA (−36.7 vs. −27.7 ml/yr; P = 0.008). Of the 86 individuals with equivocal ILA, 20 (23%) exhibited progression during the follow-up period; of these, 19 progressed to definite ILA. Conclusions: Individuals with equivocal ILA showed a significant tendency for FVC decline compared with those without ILA. A considerable number of cases progressed to definite ILA, warranting careful attention. Clinicians should be aware that even mild interstitial changes that do not meet the current criteria for ILA may deteriorate.
- 1 March 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (3) , 387-394
Prognosis of Equivocal Interstitial Lung Abnormalities in a Health Check-Up Population
Rationale: Equivocal interstitial lung abnormality (ILA) involves less than 5% of any lung zone or presents unilaterally without satisfying the diagnostic criteria for ILA. However, the prevalence and prognosis of equivocal ILA are unknown. Objectives: We sought to investigate the prevalence and long-term prognosis of equivocal ILA. Methods: This retrospective cohort study included individuals who underwent chest computed tomography as part of a health check-up program in 2010 at St. Luke’s International Hospital in Tokyo, Japan. ILA and equivocal ILA were diagnosed using the Fleischner Society criteria. The primary outcome was the annual rate of forced vital capacity (FVC) decline in the groups with ILA, equivocal ILA, and no ILA, evaluated using a mixed-effects model. Radiological progression was also evaluated. Results: Among the 20,896 individuals included in the study, ILA and equivocal ILA were present in 2.0% (95% confidence interval = 1.8–2.2) and 0.4% (95% confidence interval = 0.4–0.5) of individuals, respectively. Follow-up pulmonary function tests were available for 18,101 (87%) individuals, with a median follow-up time of 8.3 years (interquartile range = 4.0–9.0). Individuals with equivocal ILA showed a significantly greater rate of FVC decline than those without ILA (−36.7 vs. −27.7 ml/yr; P = 0.008). Of the 86 individuals with equivocal ILA, 20 (23%) exhibited progression during the follow-up period; of these, 19 progressed to definite ILA. Conclusions: Individuals with equivocal ILA showed a significant tendency for FVC decline compared with those without ILA. A considerable number of cases progressed to definite ILA, warranting careful attention. Clinicians should be aware that even mild interstitial changes that do not meet the current criteria for ILA may deteriorate.